Antitumor drug for intermittent administration of FGFR inhibitor
The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses.
1. A method of treating a cancer patient, the method comprising
administering a 3,5-disubstituted benzene alkynyl compound or a salt thereof on an administration schedule consisting of at least twice a week and a dosing interval between a day of administration and the next day of administration being at least one day, the 3,5-disubstituted benzene alkynyl compound being represented by Formula (I):
wherein R 1 is the same or different, and each represents C 1 -C 6 alkyl;
X 1 and X 2 independently represent N or CH;
Y is a group represented by Formula (A):
wherein the divalent moiety represented by
is a nitrogen-containing C 3 -C 10 heterocycloalkylene group, a group represented by Formula (B):
wherein the divalent moiety represented by
is a C 3 -C 10 cycloalkylene group, or a group represented by Formula (C):
wherein the divalent moiety represented by
is a C 6 -C 12 arylene group;
R 2 is hydrogen, C 2 -C 6 alkynyl, —C(═O)OR x , —C(═O)N(R x )(R y ), hydroxy-C 1 -C 6 alkyl, di(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, or C 2 -C 9 heteroaryl optionally having R 3 ; and R 3 is C 1 -C 6 alkyl or di(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl;
Z is —C(R 4 )═C(R 5 )(R 6 ) or —C≡C—R 7 ;
R 4 , R 5 , and R 6 are the same or different, and each represents hydrogen, halogen, C 1 -C 6 alkyl optionally having R 8 , or a group represented by Formula (D):
wherein the monovalent moiety represented by
is a nitrogen-containing C 3 -C 10 heterocycloalkyl group,
R 7 is hydrogen, C 1 -C 6 alkyl, or hydroxy-C 1 -C 6 alkyl;
R 8 is —OR x or —N(R x )(R y );
R 9 is C 1 -C 6 alkyl, halogen, or —OR x ;
R x and R y are the same or different, and each represents hydrogen, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, di(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, or C 1 -C 6 alkoxy-C 1 -C 6 alkyl;
l is an integer of 0 to 3;
m is an integer of 1 to 3; and
n is an integer of 0 to 2,
wherein said 3,5-disubstituted benzene alkynyl compound is (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one.
2. The method according to claim 1 , wherein the administration schedule is based on a 1-week cycle.
3. The method according to claim 1 , wherein the administration schedule is based on a 1-week cycle, in which the 3,5-disubstituted benzene alkynyl compound or a salt thereof is administered at least twice and the interval between a day of administration and the next day of administration being one to three days per cycle, and this cycle is performed once or repeated twice or more.
4. The method according to claim 1 , wherein the effective amount is 0.05 to 1,000 mg for an oral preparation, 0.01 to 500 mg for an injection, and 1 to 1,000 mg for a suppository.
5. The method according to claim 1 , wherein the 3,5-disubstituted benzene alkynyl compound is administered orally.
6. The method according to claim 1 , wherein the administering includes administering a pharmaceutical preparation comprising the 3,5-disubstituted benzene alkynyl compound and a pharmaceutical carrier.
7. The method according to claim 1 , wherein the administering includes administering a pharmaceutical preparation comprising the 3,5-disubstituted benzene alkynyl compound and a pharmaceutical carrier comprising at least one carrier selected from the group consisting of excipient, binder, disintegrant, lubricant, colorant, solvent, solubilizing agent, suspending agent, isotonizing agent, buffer, and soothing agent.
8. The method according to claim 1 , wherein the cancer patient is diagnosed with cancer selected from the group consisting of head and neck cancer, esophagus cancer, colon cancer, rectum cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, lung cancer, ovarian cancer, cervical cancer, endometrial cancer, renal cancer, bladder cancer, prostate cancer, testicular tumor, osteosarcoma, soft-tissue sarcoma, blood cancer, multiple myeloma, skin cancer, brain tumor, and mesothelioma.
9. The method according to claim 1 , wherein the patient is diagnosed with gastric cancer.
10. The method according to claim 1 , wherein the patient is diagnosed with liver cancer.
11. The method according to claim 1 , wherein the patient is diagnosed with cholangiocarcinoma.
12. The method according to claim 1 , wherein the patient is diagnosed with breast cancer.
13. The method according to claim 1 , wherein
the 3,5-disubstituted benzene alkynyl compound is (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one;
the effective amount is 0.05 to 1,000 mg;
the 3,5-disubstituted benzene alkynyl compound is administered orally; and
the cancer patient is diagnosed with gastric cancer.
14. The method according to claim 1 , wherein
the 3,5-disubstituted benzene alkynyl compound is (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one;
the effective amount is 0.05 to 1,000 mg;
the 3,5-disubstituted benzene alkynyl compound is administered orally; and
the cancer patient is diagnosed with liver cancer.
15. The method according to claim 1 , wherein
the 3,5-disubstituted benzene alkynyl compound is (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one;
the effective amount is 0.05 to 1,000 mg;
the 3,5-disubstituted benzene alkynyl compound is administered orally; and
the cancer patient is diagnosed with cholangiocarcinoma.
16. The method according to claim 1 , wherein
the 3,5-disubstituted benzene alkynyl compound is (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one;
the effective amount is 0.05 to 1,000 mg;
the 3,5-disubstituted benzene alkynyl compound is administered orally; and
the cancer patient is diagnosed with breast cancer.
17. A method of suppressing weight loss during treatment with a 3,5-disubstituted benzene alkynyl compound in a cancer patient, comprising administering a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one to the cancer patient on an administration schedule consisting of at least twice a week with an interval of at least one day.
18. A method of suppressing blood phosphorus level increase during treatment with a 3,5-disubstituted benzene alkynyl compound in a cancer patient, comprising administering a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one to the cancer patient on an administration schedule consisting of at least twice a week with an interval of at least one day.